Functional roles of CTCF in breast cancer

키워드

참고문헌 (64)

1. Filippova GN, "Tumorassociated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity", Cancer Res, 62, pp.48~52 (2002)
2. Nora EP, "Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization", Cell, 169, pp.930~944 (2017)
3. Fiorito E, "CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions", Nucleic Acids Res, 44, pp.10588~10602 (2016)
4. Barutcu AR, "SMARCA4 regulates gene expression and higher-order chromatin structure in proliferating mammary epithelial cells", Genome Res, 26, pp.1188~1201 (2016)
5. Phillips JE, "CTCF: master weaver of the genome", Cell, 137, pp.1194~1211 (2009)
6. Ong CT, "CTCF: an architectural protein bridging genome topology and function", Nat Rev Genet, 15, pp.234~246 (2014)
7. Jerkovic I, "Genome- Wide Binding of Posterior HOXA", D Transcription Factors Reveals Subgrouping and Association with CTCF, 2017, pp.13, e1006567~
8. Nakamoto M, "The Glucocorticoid Receptor Regulates the ANGPTL4 Gene in a CTCF-Mediated Chromatin Context in Human Hepatic Cells", PLoS One, 12, pp.e0169225~ (2017)
9. Hsu SC, "The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries", Mol Cell, 66, pp.102~116 (2017)
10. Chen L, "An Ectopic CTCF Binding Element Inhibits Tcrd Rearrangement by Limiting Contact between Vdelta and Ddelta Gene Segments", J Immunol, 197, pp.3188~3197 (2016)
11. Braikia FZ, "Inducible CTCF insulator delays the IgH 3' regulatory regionmediated activation of germline promoters and alters class switching", Proc Natl Acad Sci U S A, 114, pp.6092~6097 (2017)
12. Chan CS, "CCCTC-binding factor confines the distal action of estrogen receptor", Cancer Res, 68, pp.9041~9049 (2008)
13. Nagy G, "Motif oriented high-resolution analysis of ChIP-seq data reveals the topological order of CTCF and cohesin proteins on DNA", BMC Genomics, 17, pp.637~ (2016)
14. Gregor A, "De novo mutations in the genome organizer CTCF cause intellectual disability", Am J Hum Genet, 93, pp.124~131 (2013)
15. Herold M, "CTCF: insights into insulator function during development", Development, 139, pp.1045~1057 (2012)
16. Bastaki F, "Identification of a novel CTCF mutation responsible for syndromic intellectual disability - a case report", BMC Med Genet, 18, pp.68~ (2017)
17. Prawitt D, "Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith- Wiedemann syndrome and Wilms' tumor", Proc Natl Acad Sci U S A, 102, pp.4085~4090 (2005)
18. Aulmann S, "CTCF gene mutations in invasive ductal breast cancer", Breast Cancer Res Treat, 80, pp.347~352 (2003)
19. Katainen R, "CTCF", cohesin-binding sites are frequently mutated in cancer, 2015, pp.47, 818~821
20. Chitayat D, "Hepatocellular carcinoma in a child with familial Russell-Silver syndrome", Am J Med Genet, 31, pp.909~914 (1988)
21. Bruckheimer E, "Russell-Silver syndrome and Wilms tumor", J Pediatr, 122, pp.165~166 (1993)
22. Weiss GR, "Testicular cancer in a Russell-Silver dwarf", J Urol, 126, pp.836~837 (1981)
23. Draznin MB, "Silver-Russell syndrome and craniopharyngioma", J Pediatr, 96, pp.887~889 (1980)
24. Kemp CJ, "CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer", Cell Rep, 7, pp.1020~1029 (2014)
25. Suzuki H, "Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers", Genes Chromosomes Cancer, 17, pp.225~233 (1996)
26. Maw MA, "A third Wilms' tumor locus on chromosome 16q", Cancer Res, 52, pp.3094~3098 (1992)
27. Cleton-Jansen AM, "At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer", Genes Chromosomes Cancer, 9, pp.101~107 (1994)
28. Lindblom A, "Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases", Cancer Res, 53, pp.3707~3711 (1993)
29. Kaiser VB, "Mutational Biases Drive Elevated Rates of Substitution at Regulatory Sites across Cancer Types", PLoS Genet, 12, pp.e1006207~ (2016)
30. Poulos RC, "Functional Mutations Form at CTCF-Cohesin Binding Sites in Melanoma Due to Uneven Nucleotide Excision Repair across the Motif", Cell Rep, 17, pp.2865~2872 (2016)
31. Zhou XL, "A screen for germline mutations in the gene encoding CCCTC-binding factor(CTCF)in familial non-BRCA1", BRCA2 breast cancer, 2004, pp.6, R187~R190
32. Tiffen JC, "The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells", Int J Cancer, 133, pp.1603~1613 (2013)
33. Venkatraman B, "Role of CTCF poly(ADP-Ribosyl)ation in the regulation of apoptosis in breast cancer cells", Indian J Med Paediatr Oncol, 36, pp.49~54 (2015)
34. Torrano V, "Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism", J Cell Sci, 119, pp.1746~1759 (2006)
35. Docquier F, "Decreased poly(ADP-ribosyl)ation of CTCF, a transcription factor, is associated with breast cancer phenotype and cell proliferation", Clin Cancer Res, 15, pp.5762~5771 (2009)
36. Butcher DT, "Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase(DNMT3B)in some sporadic breast tumours", Eur J Cancer, 43, pp.210~219 (2007)
37. Wang D, "The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer", DNA Cell Biol, 33, pp.581~590 (2014)
38. Del Campo EP, "CTCF and CTCFL mRNA expression in 17beta-estradioltreated MCF7 cells", Biomed Rep, 2, pp.101~104 (2014)
39. Martin-Kleiner I, "BORIS in human cancers -- a review", Eur J Cancer, 48, pp.929~935 (2012)
40. Mendez-Catala CF, "A novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells", Neoplasia, 15, pp.898~912 (2013)
41. Mustafa M, "CTCF negatively regulates HOXA10 expression in breast cancer cells", Biochem Biophys Res Commun, 467, pp.828~834 (2015)
42. Teif VB, "Nucleosome repositioning links DNA (de)methylation and differential CTCF binding during stem cell development", Genome Res, 24, pp.1285~1295 (2014)
43. Wang H, "Widespread plasticity in CTCF occupancy linked to DNA methylation", Genome Res, 22, pp.1680~1688 (2012)
44. Victoria-Acosta G, "Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding", Sci Rep, 5, pp.14838~ (2015)
45. Peng Z, "Epigenetic repression of RARRES1 is mediated by methylation of a proximal promoter and a loss of CTCF binding", PLoS One, 7, pp.e36891~ (2012)
46. Yao Z, "The effect of epigenetic silencing and TP53 mutation on the expression of DLL4 in human cancer stem disorder", Oncotarget, 7, pp.62976~62988 (2016)
47. de Souza Rocha Simonini P, "Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells", Cancer Res, 70, pp.9175~9184 (2010)
48. Soto-Reyes E, "Disruption of CTCF at the miR-125b1 locus in gynecological cancers", BMC Cancer, 12, pp.40~ (2012)
49. Jiang F, "MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo", BMC Cancer, 11, pp.425~ (2011)
50. Zhang Y, "CCCTC-binding factor acts upstream of FOXA1 and demarcates the genomic response to estrogen", J Biol Chem, 285, pp.28604~28613 (2010)
51. Tang Z, "CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription", Cell, 163, pp.1611~1627 (2015)
52. Seitan VC, "Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments", Genome Res, 23, pp.2066~2077 (2013)
53. Heidari N, "Genome-wide map of regulatory interactions in the human genome", Genome Res, 24, pp.1905~1917 (2014)
54. Wu Q, "The BRG1 ATPase of human SWI", SNF chromatin remodeling enzymes as a driver of cancer, 2017, pp.9, 919~931
55. Bai J, "BRG1 is a prognostic marker and potential therapeutic target in human breast cancer", PLoS One, 8, pp.e59772~ (2013)
56. Wu Q, "Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells", Oncotarget, 7, pp.27158~27175 (2016)
57. Shukla S, "CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing", Nature, 479, pp.74~79 (2011)
58. Dutertre M, "Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer", Cancer Res, 70, pp.760~3770 (2010)
59. Ross-Innes CS, "A co-ordinated interaction between CTCF and ER in breast cancer cells", BMC Genomics, 12, pp.593~ (2011)
60. Docquier F, "Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis", Cancer Res, 65, pp.5112~5122 (2005)
61. Meeran SM, "Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines", PLoS One, 5, pp.e11457~ (2010)
62. Klenova EM, "The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer", Semin Cancer Biol, 12, pp.399~414 (2002)
63. D'Arcy V, "BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours", Br J Cancer, 98, pp.571~579 (2008)
64. Dougherty CJ, "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS", Biochem Biophys Res Commun, 370, pp.109~112 (2008)

관련 논문AI추천